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The fuel preference of human musde mitochondria has been given. Substrates which are oxidized with low velocity 
cannot be used to detect defects in oxidative phosphorylation. After general anaesthesia, the oxygen uptake with the 
different substrates is much lower than after local analgesia. The latter was therefore used in the subsequent study. In 
15 out of 18 patients with ocular myopathy, defects in oxidative phosporylation could be detected in isolated muscle 
mitochondria prepared from freshly biopsied tissue. Measurement of the activity of segments of the respiratory chain in 
homogenate from frozen muscle showed no, or minor defects. In two of these patients showing exercise intolerance, 
decreased oxidation of NAD +-linked substrates and apparently normal mitochondrial DNA, further study revealed 
deficiency of pyruvate dehydrogenase in a girl with ptosis and a high K m of complex I for NADH in a man. Both 
patients responded to vitamin therapy. 
In~'oduction 
The study of failing mitochondria in man is a rapidly 
expanding field of interest [1-12]. Mitochondrial dys- 
function is encountered in an increasing number of 
patients, and deficiencies have been reported of more 
than 65 mitochondrial proteins (enzymes or carriers) [7]. 
For the detection of defects in the mitochondrial energy 
transduction, skeletal muscle is the preferred tissue, also 
when the involvement of other organs in the disease 
process is more prominent. 
Extensive research revealed that many patients in 
fact suffered from multiple mitochondrial defects [7,15- 
17]. In order to detect these defects we advocate a 
functional study of isolated mitochondria from freshly 
biopsied muscle in combination with assay of relevant 
mitochondrial activities and muscle markers in homo- 
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genate from frozen muscle [8,13,14,18,19]. In the pre- 
sent work this approach was used for the investigation 
of 18 patients with ocular myopathy. 
In chronic external ophthalmoplegia (CPEO), weak- 
ness may be confined to the eye muscles. More often, it 
is only part of the clinical picture. The Kearns-Sayre 
syndrome has been separated out as a distinct form of 
CPEO and characterized by onset in childhood or 
adolescence, atypical retinopathy, heart block and raised 
CSF protein. Young patients with CPEO may develop 
the full Kearns-Sayre syndrome later [20,21]. 
Many groups tried to unravel the etiology of the 
ocular myopathies [1,19-42]. As suggested by the in- 
creased mitochondrial masses in part of the muscle 
fibres of most patients and by the increased blood 
lactate levels, defective mitochondria could play a role 
in the pathophysiology of the disease. An impressive 
amount of different mitochondrial defects have been 
reported in one or more of the patients tudied (some 
were normal), such as abnormal oxidative phosporyla- 
tion in isolated muscle mitochondria [1,19,20,22,23,26, 
34,40], decreased activity or concentration of CoQ 
[1,29,31,35,41], Complex I [19,40], Complex I + IV [34], 
Complex III [1], Complex III + IV [1,24], Complex IV 
[30,32,35,37], complete absence of Complex IV in some 
0005-2728/90/$03.50 © 1990 Elsevier Science Publishers B.V. (Biomedical Division) 
212 
muscle fibres only [25,27], uncoupler-stimulated Mg 2÷- 
ATPase [20], palmitoyl-CoA synthetase [28], mitochon- 
drial translation product [33], Complex II [39], Complex 
I and/or II!, Complex I and/or IV [40], a defective 
interaction between cytochrome c and Complex IV [37] 
and finally heteroplasmy of mitochondrial DNA 
[36,38,40,42], with different amounts of the deleted 
mitochondrial DNA of the same size in different tissues 
[42]. It is obvious that ocular myopathy is caused by a 
variety of different mitochondrial defects. Each of these 
defects, on the other hand, may give rise to a mitochon- 
drial disease without involvement of the eye muscles. 
Methods 
Mitochondria were isolated from 0.12 g or more of 
freshly biopsied muscle, obtained under local analgesia 
(lidocain plus epinephrine), within 1.5 h, according to 
the procedure of Bookelman et al. [43]. The surgical 
patients received ifferent combinations of anaesthetics 
(N20 , ethrane, sodium ~,-hydroxybutyrate), muscle re- 
laxants (succinylcholine chloride, pancuronium 
bromide) and analgetic (fentanyl). The biopsies were 
taken at the end of the operation, which lasted 2-3 h 
from the onset of pharmacological pre-treatment. The 
following assays were performed: oxidative phospho- 
rylation with various substrates (concentrations see Ta- 
ble I) was carried out in the presence of glucose, Mg 2+ 
and hexokinase [44] as described in Ref. 13. The oxygen 
uptake rate with ascorbate plus TMPD has been cor- 
rected for auto-oxidation. The P/O ratios (mol glucose 
6-phosphate formed/0.5 mol 02 consumed) were de- 
termined by sampling just before the addition of ADP 
to correct for the presence of mitochondrial denine 
nucleotides [45]. This gave rise to a considerable de- 
crease in P/O ratios (compare Ref. 13). The average 
P/O ratios with pyruvate plus malate, glutamate plus 
malate, palmitoylcarnitine plus malate, succinate plus 
rotenone and ascorbate plus TMPD in the control pa- 
tients were 1.66, 1.73, 1.80, 1.19 and 0.44 respectively, 
and were not significantly different in the other groups. 
Mg2+-ATPase was measured without and with 2,4-di- 
nitrophenol [13]. [U-14C]Palmitate oxidation was mea- 
sured with 1 mM KCN to measure the peroxisomal beta 
oxidation, and with 0.5 mM L-carnitine to measure the 
mitochondrial contribution as well [46]. Malonyl-CoA 
decarboxylase was measured as in Ref. 8, without and 
with detergent and showed a high level of integrity of 
the inner membranes. The assays in the homogenate 
were carried out as described in Ref. 19. Pyruvate 
dehydrogenase and 2-ketoglutarate d hydrogenase w re 
determined as in Ref. 47. 
DNA was isolated from 1-5 mg muscle. The tissue 
was lysed in 330 #1 of 50 mM Tris, 100 mM EDTA, 200 
mM NaC1 and 1% SDS (pH 9.0). Proteinase K was 
added to a final concentration of 0.2 mg/ml and the 
TABLE I 
Fuel preference of human muscle mitochondria 
Oxidative substrates Oxygen uptake Stimulation of n a 
(mM) rate (ng atom 0 2 per oxygen uptake 
rain per mg protein) rate by ADP (RCI) 
NAD +-linked 
Pyruvate 5+L-malate 2.5 82+ 5 (50-144) b 2.48+0.17 (1.52-4.05) b 22 
Glutamate 5 + malate 2.5 82 + 7 (45-170) 2.41 + 0.13 (1.36-3.75) 22 
2-Ketoglutarate 10 59+ 5 (41-181) 2.11+0.21 (1.56-4.42) 14 
DL-Acetylcarnitine 2.5 
+malate0.5 52+ 4 (31- 81) 2.02+0.13 (1.44-3.09) 14 
DL-3-Hydroxybutyrate 10 18 1.00 1 
DL-Isoeitrate 10 18+ 6 (11- 29) 0.70+0.11 (0.50-0.86) 3 
NAD +- and CoQ-linked 
Palmitoylcarnitine 0.02 
+malate0.6 68+ 5 (40-111) 2.16+0.16 (1.35-4.25) 22 
CoQ-linked 
Succinate 5 
+rotenone0.003 104+ 8 (62-196) 2.175:0.11 (1.50-3.38) 22 
Duroquinol 0.75 mM 
+ catalase 154 + 21 (100-212) 2.25 + 0.48 (1.27-4.09) 5 
DL-Glycerol 3-phosphate 10 23 5 :4  (12- 36) 1.11 5:0.09 (0.88-1.52) 7 
Cytochrome c-linked 
Ascorbate 5 + TMPD 0.6 344 + 13 (231 + 469) 1.65 5:0.07 (1.28-2.79) 22 
a n = number of patients tested. 
b Values + S.E.M.; range in parentheses. 
tissue was digested for at least 16 h at 37 °C until lysis 
was complete. A 6 M NaC1 solution was added to a 
final concentration of 1.5 M NaC1 [48]. Protein and 
SDS were precipitated by centrifugation for 10 min at 
1000 × g. DNA was precipitated from the supernatant 
by adding 2 vol. of ethanol followed by centrifugation 
for 10 min at 12000 × g. The supernatant was dis- 
carded, and after vacuum evaporation the DNA pellet 
was dissolved in 10/~1 bidest per mg of tissue. Average 
DNA yield is 10 #g per mg muscle tissue. 
For restriction analysis, 10/~1 DNA suspension was 
restricted with BamHI and separated on a 0.8% agarose 
gel [49]. DNA was blotted onto Genescreen Plus and 
hybridized [50] with a [32p]dCTP random prime labelled 
mitochondrial DNA clone containing the 16 S and 12 S 
ribosomal RNA genes (a generous gift of Dr. G. At- 
tardi). Filters were exposed to Kodak XAR-5 films for 
72 h using an intensifying screen. 
Results and Discussion 
Substrates of human muscle mitochondria 
Mitochondria in different tissues and cells oxidize 
substrates with different rates according to their meta- 
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bolic role in the cell. Table I shows the oxygen uptake 
rates with different oxidative substrates, catalyzed by 
human skeletal muscle mitochondria. Isocitrate, 3-hy- 
droxybutyrate and glycerol 3-phosphate are slowly 
oxidized. The former substrate because of the absence 
of the citrate carrier in muscle mitochondria [51], and 
the latter substrates due to the fact that their dehydro- 
genases have a relatively low activity. The stimulation 
of the 02 uptake rate with ADP (RCI, respiratory 
control index) is low with these substrates (Table I). A 
low respiratory rate is accompanied by a low RCI. In 
earlier work we found that this apparently loose cou- 
pling occurred when the respiratory rate fell below 30 
ngatom 02 per min per mg protein [45]. The integrity of 
the mitochondrial oxidative phosphorylation can only 
be challenged with substrates which are oxidized with a 
relatively high rate and RCI. The other substrates of 
Table I meet these criteria. When possible, we studied 
oxidative phosphorylation with the substrates used in 
Table II. When more mitochondria were available, and 
the oxidative phosphorylation was not normal, we tried 
to identify the defect more precisely by using some of 
the other substrates. When only a few oxygen traces 
TABLE II 
Oxidatioe phosphorylation i isolated muscle mitochondria npatients with ocular myopathy and in control patients, both groups after local analgesia nd 
in surgical patients after general anaesthesia 
Nr., number. Age is expressed in years. Sex: F, female and M, male. Syndr., syndrome; CPEO, chronic progressive external ophthalmoplegia; KSS, 
Kearns-Sayre syndrome. The oxygen uptake rates were measured in the presence of ADP and Pi at 25 °C  with Pyr (pyruvate plus malate), Glut 
(glutamate plus malate), Palm (palmitoylcarnitine plus malate), Succ (succinate plus rotenone), Asc (ascorbate plus TMPD) and expressed in 
ngatoms of oxygen consumed per min per mg protein. RCI, respiratory control index, the stimulation of the oxygen uptake rate by ADP with 
ascorbate plus TMPD. The mitochondrial ATP synthetase was measured as Mg2+-ATPase and expressed in nmol ATP per min per mg protein. 
DNP, 2,4-dinitrophenol. 
No. Age Sex Syndr. O2-uptake rates with RCI 
Pyr Glut Palm Succ Asc Asc 
ATPase 
- DNP + DNP 
1 8 F CPEO 20 31 32 81 349 1.56 33 270 
2 11 M KSS 63 69 60 79 233 1.76 5 531 
3 12 F KSS 23 31 23 55 283 1.29 65 341 
4 18 M KSS 36 30 30 72 213 1.89 89 447 
5 21 M KSS 18 38 26 31 341 1.52 42 1221 
6 23 M CPEO 57 54 42 61 314 1.52 43 638 
7 26 M CPEO 13 26 21 93 244 1.58 61 767 
8 28 F CPEO 47 42 54 107 379 1.45 14 129 
9 31 F CPEO 28 28 30 50 167 0.96 24 257 
10 31 M CPEO 9 9 41 13 207 1.24 30 759 
11 32 M KSS 67 73 70 13 377 1.78 29 600 
12 35 M CPEO 80 69 60 105 374 1.36 15 492 
13 39 M CPEO 67 63 42 63 225 1.15 77 309 
14 39 M CPEO 42 38 43 78 300 0.87 54 303 
15 41 M CPEO 51 46 35 54 250 1.23 41 547 
16 42 M CPEO 15 20 22 45 177 1.38 58 229 
17 46 F KSS 33 33 32 58 200 1.26 9 111 
18 53 F CPEO 80 92 69 86 315 1.17 19 427 
Controls (n = 22) 82 82 68 104 344 1.65 44 603 
S.E.M. 5 7 5 8 13 0.07 10 55 
Surgical patients (n = 5) 31 36 26 41 164 1.55 26 434 
S.E.M. 5 4 6 5 28 0.11 12 103 
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could be obtained, we preferred combined assays with 
substrates and inhibitors [13]. 
Control patients 
It is important hat the oxidative performance of 
patient mitochondria s compared with proper controls. 
The number of mitochondria is decreased in fetal, 
neonatal and disused muscle, and increased in en- 
durance sporters. Therefore we prefer control patients 
with about the same exercise pattern. These patients 
were biopsied because of the fact that they suffered 
from chronic muscle problems. With clinical, 
histopathological and biochemical methods no evidence 
could be detected for a neuromuscular defect. Since the 
results obtained in different laboratories differ greatly 
[52], control and patient studies must be performed in 
the same laboratory. 
Surgical patients are often used as controls. In the 
past we have found that their muscle contained less 
carnitine than our control patients [53], and we 
wondered if the mitochondrial function was disturbed. 
This was indeed the case (Table II). We found a severe 
impairment of the respiratory rates with all substrates 
tested. The NAD+-linked substrates and succinate were 
oxidized with 40% and ascorbate with 48% of control 
activity. Surprisingly, the efficiency and coupling of 
oxidative phosphorylation were not significantly altered 
as expressed by the normal P/O values (not shown) and 
RCI values. Also, ATP synthetase, measured as Mg 2+- 
ATPase activity, was similar to control values. The basic 
activity was low and the stimulation by uncoupler high. 
For the complete investigation and a discussion see Ref. 
54. 
Hoppel et al. [55] presented control mitochondria 
from skeletal muscle of surgical patients with average 
respiratory rates of 31 ngatom O 2 per min per mg 
protein with pyruvate plus malate, 25 with glutamate, 
26 with palmitoylcarnitine plus malate and 52 for suc- 
cinate plus rotenone, measured at 30 ° C, agreeing very 
well with our observations at25 ° C. 
Ocular myopathy 
The results of the oxidative phosphorylation in the 
individual patients with ocular myopathy are sum- 
marized in Table II. From comparison with the results 
of the activity of the segments of the respiratory chain 
(Table III), it is clear that most defects in the mitochon- 
drial energy transduction can only be measured in in- 
tact mitochondria, nd not in homogenate from frozen 
muscle. Normal oxidative phosphorylation was found in 
TABLE III 
The activity of segments of the mitochondrial respiratory chain, the amount of protein and carnitine and the actioity of creatine kinase in muscle 
homogenates ofpatients with ocular myopathies and control patients 
I, rotenone-sensitive NADH oxidase, in tamol NADH/min .  II, succinate dehydrogenase, in #mol 2-p-iodophenyl-3-p-nitrophenyl-5-phenyltetra- 
zol ium/min. II + III, antimycin-sensitive succinate cytochrome c reductase, in #tool cytochrome c/min. IV, Cytochrome c oxidase, in first order 
rate constant k/nfin. Prot, protein, in nag. Cam, total carnitine, in /~mol. CK, creatine kinase, in #mol creatine/min. The data above were 
calculated per g wet weight. The sizes of the mitochondrial DNA were given in kilobase. 
Nr. Respiratory chain Mitochondrial DNA 
I II I I+ I I I  IV Prot Cam CK main band(s) satelfite 
1 2.14 0.93 6.88 115 144 3.56 307 16.5 No 
2 3.45 0.78 107 218 2.52 259 16.5 12.5 
3 3.28 1.46 9.89 124 170 2.41 367 16.5 33.0 
4 1.40 0.81 5.73 29 183 2.77 418 13.0 16.5 
5 2.92 0.87 1.57 137 180 5.37 248 
6 4.87 0.95 4.84 164 153 3.11 277 16.5 no 
7 2.67 0.60 2.99 90 2.28 341 16.5 no 
8 2.40 0.74 3.81 102 186 3.62 241 16.5 14.0 
9 2.98 0.97 5.39 108 213 2.91 260 16.5 33.0 
10 0.80 4.82 80 141 2.92 399 
11 0.62 1.28 144 4.46 256 
12 3.54 0.93 5.29 76 130 3.30 296 16.5 no 
13 2.14 0.88 3.85 55 105 2.91 315 16.5; 14.0 no 
14 1.64 0.59 8.70 57 85 2.34 266 16.5 13.0 
15 0.82 4.71 67 186 2.68 288 
16 1.01 0.48 2.21 34 185 2.44 278 33.0 no 
17 2.10 1.16 3.48 66 198 2.10 286 16.5 no 
18 1.75 0.77 4.10 94 183 3.71 197 16.5 no 
Contr. 3.19 0.72 3.99 90 174 3.96 307 16.5 no 
S.E.M. 0.26 0.04 0.43 7 6 0.09 12 
n 10 58 21 16 53 59 50 
three patients, while it was abnormal in 15 patients. 
Four of them showed a low oxidation rate with the 
NAD+-l inked substrates only, one showed also a low 
rate with succinate, one showed only a low oxidation 
rate with succinate (for discussion see Ref. 19), three 
showed low rates with all substrates. Uncoupler-stimu- 
lated Mg2+-ATPase had a low activity in two patients, 
and an abnormally low stimulation of the respiratory 
rate with ascorbate plus TMPD by ADP was encoun- 
tered in six patients, pointing to a defect in complex V, 
the adenine nucleotide translocator or the Pi-transloca- 
tor. Mitochondrial enzyme activities were normal in 14 
of the patients. Two showed a decreased activity of 
complex I and IV and two of complex IV only. These 
decreases could not explain the severe depression of the 
oxidative phosphorylation. The muscle markers total 
carnitine and creatine kinase were normal or slightly 
below normal in all patients (Table III). 
In 14 patients, restriction analysis was performed 
with mitochondrial DNA.  Apparently normal mtDNA 
was detected in six, heteroplasmy in six, and mtDNA of 
twice the size in controls was found in three patients. In 
one of these it is the only band visible. Two of the 
patients showed the lowest oxidation rate with ascor- 
bate. mtDNA of double length has not been reported 
before and its appearance is puzzling. 
Further research into the nature of the mitochondrial 
defect in muscle homogenate was successful in a girl 
(patient 1) and a man (patient 7) both suffering from 
lifelong exercise intolerance by fatigue, having de- 
creased oxidation rate with NAD+-l inked substrates 
and (apparently) normal mtDNA.  The gift showed a 
deficiency of pyruvate dehydrogenase (after preincuba- 
tion with Ca 2+ plus Mg 2+ 188 mU/g  wet weight vs. 
922 + 102 (S.E.) mU/g  wet weight in nine controls. 
2-Ketoglutarate dehydrogenase 442 mU/g  wet weight 
vs. 1091-]-156 (S.E.) in 11 controls), She received 
thiamin and riboflavin, and her ptosis disappeared 
within 8 months, while her plasma lactate decreased 
from 4.2 mM to 1.9 mM (controls: 0.6-1.8 mM). In the 
man an increased K m of NADH oxidase for complex I
was found (Ref. 19) and he improved significantly by 
nlcotinamide. The man had a normal activity of pyru- 
vate dehydrogenase. 
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